2024
Gut microbiome profiles to exclude the diagnosis of hepatic encephalopathy in patients with cirrhosis
Bajaj J, O’Leary J, Jakab S, Fagan A, Sikaroodi M, Gillevet P. Gut microbiome profiles to exclude the diagnosis of hepatic encephalopathy in patients with cirrhosis. Gut Microbes 2024, 16: 2392880. PMID: 39189586, PMCID: PMC11352695, DOI: 10.1080/19490976.2024.2392880.Peer-Reviewed Original ResearchConceptsGut microbiome profilesHepatic encephalopathyGut microbiota testMicrobial speciesMicrobiome profilesTraining cohortValidation cohortHE diagnosisStool microbiotaMulticenter prospective cohortDiagnosis of hepatic encephalopathyMulticenter validation cohortNeuropsychological testsNanopore analysisSemi-quantitative questionnaireGutStandard neuropsychological testsProspective cohortIdentified patientsPatientsGold standardCohortDisease processCognitive complaintsDiagnosis
2007
Mycophenolate mofetil for drug-induced vanishing bile duct syndrome.
Jakab SS, West AB, Meighan DM, Brown RS, Hale WB. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World Journal Of Gastroenterology 2007, 13: 6087-9. PMID: 18023105, PMCID: PMC4250896, DOI: 10.3748/wjg.v13.45.6087.Peer-Reviewed Original ResearchConceptsBile duct syndromeAmoxicillin/clavulanateMycophenolate mofetilLow-dose mycophenolate mofetilSequential liver biopsiesInosine monophosphate dehydrogenase inhibitorSustained remissionCholestatic patternImmunosuppressive therapyElderly patientsProlonged cholestasisLiver biopsyLiver injuryMofetilPatientsComplete withdrawalAzathioprineSyndromeClavulanateDehydrogenase inhibitorCirrhosisCorticosteroidsPrednisoneRemissionCholestasis